Edward A. Stadtmauer

36.1k total citations · 6 hit papers
331 papers, 14.0k citations indexed

About

Edward A. Stadtmauer is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Edward A. Stadtmauer has authored 331 papers receiving a total of 14.0k indexed citations (citations by other indexed papers that have themselves been cited), including 218 papers in Hematology, 156 papers in Oncology and 94 papers in Molecular Biology. Recurrent topics in Edward A. Stadtmauer's work include Multiple Myeloma Research and Treatments (145 papers), Hematopoietic Stem Cell Transplantation (83 papers) and Cancer Treatment and Pharmacology (47 papers). Edward A. Stadtmauer is often cited by papers focused on Multiple Myeloma Research and Treatments (145 papers), Hematopoietic Stem Cell Transplantation (83 papers) and Cancer Treatment and Pharmacology (47 papers). Edward A. Stadtmauer collaborates with scholars based in United States, Canada and Germany. Edward A. Stadtmauer's co-authors include Dan T. Vogl, David Porter, Donald E. Tsai, Stephen J. Schuster, Selina M. Luger, Sagar Lonial, Alison W. Loren, Rubén Niesvizky, Adam D. Cohen and Antonella Aiello and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Edward A. Stadtmauer

323 papers receiving 13.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

2007 925 citations Edward A. Stadtmauer et al. profile →
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

2001 654 citations Edward A. Stadtmauer et al. profile →
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

2009 579 citations Edward A. Stadtmauer et al. Blood profile →
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

2006 553 citations Amrita Krishnan, Edward A. Stadtmauer et al. profile →
bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia

1993 533 citations Edward A. Stadtmauer et al. Blood profile →
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

2015 434 citations Alfred L. Garfall, Wei‐Ting Hwang et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Edward A. Stadtmauer	6.9k	6.7k	5.2k	2.3k	2.2k	331	14.0k
Frits van Rhee	6.4k 0.9×	9.9k 1.5×	6.6k 1.3×	1.3k 0.6×	2.1k 1.0×	421	14.0k
Ola Landgren	6.0k 0.9×	9.8k 1.4×	6.4k 1.2×	3.1k 1.4×	2.3k 1.1×	504	17.6k
H. Miles Prince	5.8k 0.9×	4.2k 0.6×	5.4k 1.1×	4.2k 1.8×	3.2k 1.5×	428	14.8k
Magnus Björkholm	4.0k 0.6×	5.6k 0.8×	5.0k 1.0×	3.2k 1.4×	2.5k 1.1×	488	16.3k
Jean‐Luc Harousseau	7.0k 1.0×	11.0k 1.6×	8.8k 1.7×	2.2k 1.0×	1.5k 0.7×	319	15.8k
Yok‐Lam Kwong	6.3k 0.9×	3.7k 0.6×	5.0k 1.0×	5.5k 2.4×	3.5k 1.6×	514	16.7k
John F. DiPersio	5.9k 0.9×	12.0k 1.8×	6.4k 1.2×	1.3k 0.6×	5.1k 2.4×	596	20.8k
Mitsune Tanimoto	5.2k 0.8×	2.8k 0.4×	4.2k 0.8×	1.5k 0.7×	2.5k 1.2×	525	13.7k
Jerome B. Zeldis	5.5k 0.8×	10.1k 1.5×	7.8k 1.5×	1.6k 0.7×	894 0.4×	202	15.4k
Christian Peschel	5.2k 0.8×	3.1k 0.5×	5.8k 1.1×	1.8k 0.8×	4.9k 2.3×	345	16.8k

Countries citing papers authored by Edward A. Stadtmauer

Since Specialization

Citations

This map shows the geographic impact of Edward A. Stadtmauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward A. Stadtmauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward A. Stadtmauer more than expected).

Fields of papers citing papers by Edward A. Stadtmauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward A. Stadtmauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward A. Stadtmauer. The network helps show where Edward A. Stadtmauer may publish in the future.

Co-authorship network of co-authors of Edward A. Stadtmauer

This figure shows the co-authorship network connecting the top 25 collaborators of Edward A. Stadtmauer. A scholar is included among the top collaborators of Edward A. Stadtmauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward A. Stadtmauer. Edward A. Stadtmauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hubbeling, Harper, Kang Yu, Michael J. LaRiviere, et al.. (2025). Outcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma. Blood Advances. 10(4). 1395–1399.

Malek, Ehsan, Leland Metheny, Pingfu Fu, et al.. (2024). Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. Transplantation and Cellular Therapy. 30(7). 698.e1–698.e10. 1 indexed citations

Sussman, Jonathan, Alfred L. Garfall, Adam D. Cohen, et al.. (2024). Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. Bone Marrow Transplantation. 60(1). 64–68. 2 indexed citations

Hasanali, Zainul S., Alfred L. Garfall, Lisa Burzenski, et al.. (2024). Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice. JCI Insight. 9(10). 3 indexed citations

Augustson, Bradley, Hira Mian, Edward A. Stadtmauer, et al.. (2024). A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 144(Supplement 1). 2000.2–2000.2. 1 indexed citations

Vogl, Dan T., Yulia Nefedova, E. Paul Wileyto, et al.. (2024). Tasquinimod, an S100A9 Inhibitor, in Combination with Ixazomib, Lenalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma. Blood. 144(Supplement 1). 7060–7060. 1 indexed citations

Banerjee, Rahul, Othman Salim Akhtar, Ciara L. Freeman, et al.. (2024). 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702. Blood. 144(Supplement 1). 81–81. 3 indexed citations

Landsburg, Daniel J., Sunita D. Nasta, Jakub Svoboda, et al.. (2023). Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells. Transplantation and Cellular Therapy. 29(8). 495–503. 3 indexed citations

Hasanali, Zainul S., Beatrice M. Razzo, Sandra P. Susanibar-Adaniya, et al.. (2023). Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma. Hematology/Oncology Clinics of North America. 38(2). 383–406. 3 indexed citations

10.

Abou‐Ismail, Mouhamed Yazan, Raphael Fraser, Leland Metheny, et al.. (2022). Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. British Journal of Haematology. 197(3). 326–338. 1 indexed citations

11.

Matthews, Andrew, Alexander E. Perl, Selina M. Luger, et al.. (2022). Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Advances. 6(13). 3997–4005. 53 indexed citations

12.

Loren, Alison W., Elizabeth O. Hexner, Mary Ellen Martin, et al.. (2022). Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies. Transplantation and Cellular Therapy. 29(2). 113–118. 2 indexed citations

13.

Bashir, Qaiser, Taiga Nishihori, Marcelo C. Pasquini, et al.. (2022). A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. Transplantation and Cellular Therapy. 29(6). 358.e1–358.e7. 5 indexed citations

14.

Cohen, Adam D., Simon F. Lacey, Megan M. Davis, et al.. (2021). The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clinical Cancer Research. 27(23). 6580–6590. 23 indexed citations

15.

Friend, Brian D., Larisa Broglie, Brent R. Logan, et al.. (2020). Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation. Blood. 136(Supplement 1). 34–35. 3 indexed citations

16.

Tsai, Donald E., Selina M. Luger, Charalambos Andreadis, et al.. (2008). A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Clinical Cancer Research. 14(17). 5619–5625. 29 indexed citations

17.

Olin, Rebecca L., Selina M. Luger, David Porter, et al.. (2005). Pegfilgrastim versus filgrastim to accelerate hematopoietic recovery after high-dose melphalan and autologous hematopoietic stem cell transplantation (ASCT) for multiple myeloma. Biology of Blood and Marrow Transplantation. 11(2). 87–87. 1 indexed citations

18.

Gerecitano, John F., Clarissa Mathias, Rosemarie Mick, et al.. (2003). Homocysteine and Prothrombin Fragment 1+2 Levels in Patients with Veno-Occlusive Disease after Stem Cell Transplantation. Journal of Hematotherapy & Stem Cell Research. 12(2). 215–223. 4 indexed citations

19.

Buckanovich, Ronald J., Carrie Tompkins Stricker, Selina M. Luger, et al.. (2002). Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy. Annals of Hematology. 81(7). 410–413. 43 indexed citations

20.

Mathias, Clarissa, Rosemarie Mick, Stephen Grupp, et al.. (2000). Soluble Interleukin-2 Receptor Concentration As a Biochemical Indicator for Acute Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation. Journal of Hematotherapy & Stem Cell Research. 9(3). 393–400. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact